TORONTO, ONTARIO--Dimethaid Research Inc. announced today that 
independent researchers conducting a study on the immune 
modulator, WF10, have been accepted to present results at the 
upcoming American Association of Immunologists' Experimental 
Biology conference in San Francisco, April 18 to 22. 

The promising results from the Mechanism of Action suggest that 
WF10 may be useful in the treatment of the symptoms associated 
with AIDS; that WF10 may prove to be useful in the treatment of 
AIDS-related dementia and that WF10 may help slow the progression 
of HIV. The material presented follows similar presentations at 
the HIV Pathogenesis conference, which took place earlier this 
month in Utah. 

Dimethaid also announced today that the option to increase its 
interest in OXO Chemie AG has been extended beyond the March 31, 
1998 deadline. Dimethaid maintains a 20 percent interest in the 
private Swiss company that holds the patent rights to WF10.  
Dimethaid also holds exclusive Canadian distribution rights for 
WF10. 

"Results to date from the Mechanism of Action study, including 
what will be presented in San Francisco, have demonstrated the 
great potential of WF10 as an immune modulator and we continue to 
be very excited about the prospects for this drug," said Rebecca 
Keeler, President and CEO of Dimethaid Research.  "Our decision on
the investment in OXO reflects prudent management of our fiscal 
resources.  The extension allows us to continue our immediate 
focus on pre-marketing preparations for PENNSAID(TM), our topical 
non-steroidal anti-inflammatory lotion for the relief of 
osteoarthritic pain, while maintaining the option to increase our 
position in OXO in the future. OXO Chemie is sufficiently funded 
to continue the development of WF10 as planned, including 
additional clinical studies for both AIDS and cancer indications."

Applications for marketing approval of PENNSAID(TM) have been made
to Canada, the United Kingdom and the United States. Dimethaid 
Research is also pursuing the development of additional 
indications for its patented transdermal delivery system in 
combination with other drugs. 

Dimethaid Research is a pharmaceutical company engaged in the 
development and commercialization of innovative therapeutic 
products which work with the body's own healing mechanisms.  

Abstracts accepted at this conference can be found at:  
www.dimethaid.com 

-30-

FOR FURTHER INFORMATION PLEASE CONTACT:

Dimethaid Research Inc.
Peter Block
Investor Relations Manager
(905) 415-1446
e-mail: pblock@dimethaid.com

Have a very nice day

Pierre